Osteopore completes neurosurgery project targeting 25000 procedures
- Osteopore has finalised its development project for a new intra-operative external ventricular drain guide.
- The company's stock remained unchanged at $0.005 following the announcement of the development milestone.
- The business is now seeking additional funding opportunities to progress the device into a clinical evaluation phase.
Regenerative medicine company Osteopore (ASX:OSX) has completed the development project for its intra-operative external ventricular drain guide, targeting a market with an estimated 20,000 to 25,000 annual procedures in the United States alone.
The milestone follows a research collaboration agreement signed with the National University Hospital on 10 March 2026 to enhance precision and safety in neurosurgery.
The completed development project comprised two distinct phases, focusing first on the design and prototyping of the guide before moving into simulated testing with dry bone models.
The project team is currently seeking additional funding opportunities to transition the medical device into its upcoming clinical evaluation phase.
Following the announcement, the Osteopore share price was unchanged at $0.005.
The company recently expanded its international operations by securing regulatory approval from the Hainan Food and Drug Administration for its separate orthopaedic devices in China.
The medical technology business specialises in manufacturing 3D-printed bioresorbable implants designed to naturally dissolve over time while facilitating healthy bone tissue growth.
